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ABSTRACT Human bocavirus 1 (HBoV1), a nonenveloped single-stranded DNA par-
vovirus, causes mild to life-threatening respiratory tract infections, acute otitis media,
and encephalitis in young children. HBoV1 often persists in nasopharyngeal secre-
tions for months, hampering diagnosis. It has also been shown to persist in pediatric
palatine and adenoid tonsils, which suggests that lymphoid organs are reservoirs for
virus spread; however, the tissue site and host cells remain unknown. Our aim was
to determine, in healthy nonviremic children with preexisting HBoV1 immunity, the
adenotonsillar persistence site(s), host cell types, and virus activity. We discovered that
HBoV1 DNA persists in lymphoid germinal centers (GCs), but not in the corresponding
tonsillar epithelium, and that the cell types harboring the virus are mainly naive, acti-
vated, and memory B cells and monocytes. Both viral DNA strands and both sides of
the genome were detected, as well as infrequent mRNA. Moreover, we showed, in B-
cell and monocyte cultures and ex vivo tonsillar B cells, that the cellular uptake of
HBoV1 occurs via the Fc receptor (FcgRII) through antibody-dependent enhancement
(ADE). This resulted in viral mRNA transcription, known to occur exclusively from dou-
ble-stranded DNA in the nucleus, however, with no detectable productive replication.
Confocal imaging with fluorescent virus-like particles moreover disclosed endocytosis.
To which extent the active HBoV1 GC persistence has a role in chronic inflammation
or B-cell maturation disturbances, and whether the virus can be reactivated, will be
interesting topics for forthcoming studies.
IMPORTANCE Human bocavirus 1 (HBoV1), a common pediatric respiratory pathogen,
can persist in airway secretions for months hampering diagnosis. It also persists in
tonsils, providing potential reservoirs for airway shedding, with the exact location,
host cell types, and virus activity unknown. Our study provides new insights into
tonsillar HBoV1 persistence. We observed HBoV1 persistence exclusively in germinal
centers where immune maturation occurs, and the main host cells were B cells and
monocytes. In cultured cell lines and primary tonsillar B cells, we showed the virus
uptake to be significantly enhanced by HBoV1-specific antibodies, mediated by the
cellular IgG receptor, leading to viral mRNA synthesis, but without detectable pro-
ductive replication. Possible implications of such active viral persistence could be
tonsillar inflammation, disturbances in immune maturation, reactivation, or cell death
with release of virus DNA, explaining the long-lasting HBoV1 airway shedding.
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Human bocavirus 1 (HBoV1), a small nonenveloped linear single-stranded DNA virusof the Parvoviridae family, was discovered in 2005 in nasopharyngeal aspirates of
children with respiratory tract infections (RTI) (1). Accumulating evidence has shown
that HBoV1 causes both upper and lower respiratory tract infections of diverse severity
and affects most children before age 7 (2, 3). After primary infection, HBoV1 can, de-
spite a vigorous antibody response, persist in the respiratory tract for at least up to
12months (4–7), explaining the frequent codetection of HBoV1 with other viruses,
hampering diagnosis. Several studies have documented intermittent excretion of
HBoV1 DNA (7–10), suggesting reinfection or reactivation by an unknown source and
mechanism.
HBoV1 DNA has frequently been detected in both palatine and adenoid (nasopha-
ryngeal) tonsils of children with chronic tonsillitis and hypertrophy but without symp-
toms of RTI (11–18). Tonsils could thus be a reservoir for virus spread. Indeed, tonsillec-
tomy seems to reduce the excretion of HBoV1 (19, 20). Notwithstanding the evidence
of HBoV1 persistence in tonsils and adenoids, the specific tissue site, cell type(s) har-
boring the virus, and virus activity, are unknown. Lu et al. found HBoV1 PCR positivity
in Ficoll-Paque-separated tonsillar mononuclear cells in 32% of the children, without
further characterization of cell types or virus activity (12).
HBoV1 has been shown to productively infect differentiated air-liquid interface cell
cultures of human airway epithelium (HAE) (21, 22). In young children, HBoV1 primary
infection is therefore thought to target the airway epithelial cells. Yet, how the virus
infects lymphoid tissues remains unknown. In Aleutian mink parvovirus infection of
permissive macrophages and parvovirus B19 (B19V) infection of presumably nonper-
missive monocytes, B cells, and endothelial cells, the virus uptake has been shown to
occur by antibody-dependent enhancement (ADE) (23–26).
Our aim was to characterize HBoV1 infection and persistence in adenotonsillar tis-
sues. We observed the persistent HBoV1 DNA in adenoids to localize exclusively in ger-
minal centers (GCs) and the cell types harboring the virus to be mainly B cells and
monocytes. Furthermore, in human B-cell and monocyte cultures, as well as ex vivo-cul-
tured tonsillar B cells, we demonstrated HBoV1 virions to enter cells by antibody-de-
pendent enhancement via the cellular Fc gamma receptor (FcgRII), leading to mRNA
transcription, indicating that synthesis of double-stranded DNA (dsDNA) had occurred
and the virus had been transported to the nucleus. We further showed that fluorescent
virus-like particles (VLPs) localize in B-cell endosomes. Nevertheless, no productive
infection was observed.
RESULTS
HBoV1 DNA persistence in tonsils and cell fractions.We searched for and quanti-
fied HBoV1 DNA with quantitative PCR (qPCR), targeting the left side (NS1 gene) of the
genome, in total DNA preparations (from tissue preparation 1 [Prep 1]) of 98 tonsillar
tissues from 79 individuals. Among the .10-year-old patients with chronic tonsillitis or
tonsillar hypertrophy, only 1 of 38 (2.6%) tonsils was positive for HBoV1 DNA (a tonsil
of a 34-year-old male). Among the children #10 years of age, 13 of 41 (32%) were posi-
tive for HBoV1 DNA in tonsil, adenoid, or both (Fig. 1). HBoV1 DNA was detected in
54% (7/13) of adenoids, 21% (10/47) of individual tonsils, and 22% (8/37) of tonsil pairs
per child. Overall, the viral DNA loads were low (median, 5.9 101 copies/106 cells;
range, 2.6 100 to 2.9 106 copies/106 cells). Among nine patients with both tonsillar
and adenoidal tissues available, HBoV1 DNA was detected in the adenoids alone in two
patients, in the tonsils alone in no patients, and in both adenoids and tonsils (of both left
and right sides) in two patients, with 24- and 5,900-fold-higher viral loads in adenoids than
in tonsils. Another qPCR, amplifying the right side (VP gene) of the HBoV1 genome, yielded
similar viral loads (see Fig. S1 in the supplemental material).
B-cell, T-cell, and monocyte fractions were enriched with magnetic beads from all
17 HBoV1 DNA-positive tonsillar tissues (10 tonsils and 7 adenoids) collected from 13
children. The tonsillar tissues comprised 65.2% B cells, 2.1% monocytes, and 22.9% T
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cells; of the latter, 75% were CD41 Th cells (Fig. S2A). Viral DNA was detected in 14/17
(82%) monocyte/macrophage fractions, in 10/17 (59%) B-cell fractions, and 5/17 (29%)
T-cell fractions. Of note, all 7 HBoV1 DNA-positive adenoids but only 7 of 10 (70%) ton-
sils had virus detectable in at least one corresponding cell fraction (Fig. 1).
A 3-year-old asymptomatic child had a very high viral load (2.9 106 copies/106 cells)
in his adenoid tissue, as well as in the isolated monocyte (9.5 106 copies/106 cells), B-cell
(2 104 copies/106 cells), and T-cell (2.8 104 copies/106 cells) fractions. In contrast, his left
and right tonsils and their subpopulations had lower HBoV1 DNA loads (#4.9 102 cop-
ies/106 cells).
Viral transcription in tonsillar tissues. The one high-load adenoid (of Prep 1)
described above was repeatedly low positive for HBoV1 NS1 mRNA (Fig. 1) (quantifica-
tion cycle [Cq] = 36 to 37 with reverse transcription-PCR [RT-PCR]), whereas NP1 and VP
mRNAs were below detection level. In the NS1 RT-PCR, the DNase I-treated RNA prep
(no-reverse transcriptase [RT] control) was negative, ruling out interfering DNA amplifi-
cation. All the bead-enriched cell fractions from this adenoid were, however, negative
for all the viral mRNAs (NP, VP, and NS1). Neither were the viral mRNAs detectable in
the remaining 10/11 tissues with lower HBoV1 DNA loads.
Prior HBoV1 immunity in the children. Twelve of the 13 HBoV1 DNA-positive chil-
dren had HBoV1-specific IgG antibodies, yet without IgM, indicating preexisting immu-
nity (Fig. 1). From the remaining child, a serum sample was not available. The overall
HBoV1 seroprevalence of the children#10 years of age was 74.4%. The 3-year-old child
described above was nonviremic and exhibited long-term HBoV1 immunity (positive
for HBoV1 IgG, negative for HBoV1 IgM). Furthermore, he was seronegative for HBoV2
and HBoV3. Altogether, only 2 children among the 12 HBoV1 DNA-positive children
with available serum were HBoV2 or 3 IgG positive (Fig. 1).
HBoV1 DNA persistence in tonsillar germinal centers. To further pinpoint the
persistence site of HBoV1 in tonsillar tissue, RNAscope in situ hybridization (RISH) tar-
geting HBoV1-VP positive-strand DNA and mRNA, was applied to fresh-frozen OCT-em-
bedded tissue sections (Prep 2). All four adenoids with medium to high viral loads
(3.5 103 to 2.9 106 copies/106 cells) showed by RISH the presence of HBoV1 DNA,
indicated as red dots in Fig. 2A and B. The viral DNA was not dispersed throughout the
adenoid tissues; instead the signals were exclusively confined to the round germinal
centers (GCs). The absolute numbers of infected cells per GC ranged from 10 to 500
with one to three dots visible per cell. In contrast, no virus was observable by VP RISH
in the seven tonsils or three adenoids with low-load HBoV1 DNA. To ensure that the
cells harbored both left and right sides of the viral genome, as well as both of the DNA
FIG 1 HBoV1 DNA and mRNA in palatine tonsils and adenoids of children below 10 years of age, DNA in their
magnetic bead-separated cell fractions, as well as serology of the HBoV1 DNA-positive children. The asterisk after
Serology indicates that 12/13 HBoV1 DNA-positive children had available serum. All separated cell fractions were
mRNA negative. IgG/M, immunoglobulin G/M; H1-3, human bocavirus 1 to 3; B, B-cell fraction; M, monocyte fraction;
T, T-cell fraction.
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strands, three of the four HBoV1 VP RISH-positive adenoids were further restained with NS
sense probes targeting the negative DNA strand on sequential tissue sections, with posi-
tive results. This NS RISH also confirmed the exclusive GC localization of HBoV1, with even
stronger signals (Fig. 2C and D). NS RISH furthermore stained the GCs of one of the two
low-viral-load tonsils of the above-mentioned 3-year-old child. The positive and negative
technical control probes worked appropriately (Fig. 2E and F). Immunohistochemistry (IHC)
with the B-cell marker CD20 (diaminobenzidine [DAB] brown) following HBoV1 VP RISH
substantiated that the virus is located in the GCs (Fig. 2G and H).
In addition, HBoV1 VP RISH of RNase A-treated sections disclosed that the signal
mainly originated from viral DNA rather than mRNA (Fig. 2I), indicating the presence of
positive-strand viral DNA of this generally negative-strand single-stranded DNA
(ssDNA) virus. Further, most of the signal remained after RNase treatment also with the
NS sense probe, as expected (data not shown). The housekeeping gene (PPIB) RISH
mRNA control showed no staining in sections similarly treated with RNase A (Fig. 2J).
Tonsillar B-cell subpopulation infected with HBoV1. From the HBoV1 DNA-posi-
tive tissues, four adenoids and two tonsils (Prep 3) were sorted by fluorescence-acti-
vated cell sorting (FACS) for B-cell subpopulations. The gating strategy is illustrated in
Fig. 3. Viral DNA was found by qPCR mainly in naive and memory B cells of three
adenoids and one tonsil and also in activated B cells of two adenoids (median,
FIG 2 HBoV1 staining of germinal centers (GCs) of adenoid sections and FACS-sorted naive B cells by RNAscope ISH (RISH). Red dots
represent HBoV1 DNA/mRNA signals. The sections were counterstained with hematoxylin (blue). (A and B) The high-load adenoid stained
with VP antisense probe showing HBoV1 positive-strand DNA/mRNA staining in the GCs (A) and a higher-magnification view (B). (C and D)
The high-load adenoid stained with NS1 sense probe showing one exceptionally dark stained GC with HBoV1 negative-strand DNA (C). A
more typical GC is shown magnified (D). Note that this sense probe gives, for unknown reasons, wider and more saturated red dots than
the VP probe. (E and F) Human reference gene PPIB and bacterial gene dapB as positive and negative controls, respectively. (G and H) IHC
staining of the B-cell marker CD20 in one adenoid following HBoV1 RISH (G) and a higher-magnification view of panel G (H). Arrows indicate
the localization of virus. (I and J) HBoV1 VP antisense-probed tissue (I) and PPIB-probed tissue (J), treated with RNase A. (K and L) One B cell
(arrow) showing HBoV1 staining in naive B cells sorted from one high viral load adenoid (K), and a few B cells showing PPIB staining in a
total tonsil cell suspension (L). Bars, 500mm (G), 200mm (C), 100mm (A), 20mm (E, F, I, and J), 10mm (B, D, K, and L), and 5mm (H). H1,
human bocavirus 1 (HBoV1); GC, germinal center; PPIB, human housekeeping gene, positive-control probe; dapB, bacterial gene, negative-
control probe; RISH, RNAscope in situ hybridization; IHC, immunohistochemistry.
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4.3 103 copies/106 cells; range, 1 101 to 7.8 105 copies/106 cells). One low-load
tonsil showed no HBoV1 DNA in any B-cell subpopulation, whereas one high-load
adenoid showed HBoV1 DNA in all four subpopulations (median, 3.3 105 copies/106
cells; range, 2.6 104 to 7.8 105 copies/106 cells). Viral DNA results in B cells of two
representative adenoids and one tonsillar tissue sample are shown in Fig. 4. However,
no significant differences in viral loads were noted between the B-cell subpopulations.
HBoV1 VP RISH of the sorted B-cell subpopulations showed HBoV1 staining only in the
high-load adenoidal naive B cells (Fig. 2K). PPIB positive-control RISH in total tonsil cells
is shown in Fig. 2L.
FIG 4 HBoV1 DNA presence in B-cell subsets (plasmablasts and naive, activated, and memory B cells)
sorted from two adenoids and one tonsil. Viral loads are presented as copies per one million cells.
FIG 3 FACS sorting of B-cell subpopulations from one representative adenoid. (A) Total cells and
singlets were selected, dead cells were excluded by 7AAD staining, and total B cells were identified
from CD191 stained cells and gated based on the expression of CD20. (B) CD201 B cells from panel A
were further plotted for the expression of IgD and CD27, which separate three subpopulations: naive
B (IgD1 CD272), activated B (IgD1 CD271), and memory B cells (IgD2 CD271). Additionally, IgD2
CD271 B cells (C) were gated from CD202 subpopulation (A) and then further gated for CD381
plasmablasts (D). FACS, fluorescence-activated cell sorting; FSC, forward scatter.
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Antibody-dependent enhancement of HBoV1 infection. The possibility of anti-
body-dependent enhancement (ADE) of HBoV1 infection was determined with ex vivo
tonsillar B cells, two human B-cell lines (GM04671-Raji and GM12878), and one mono-
cyte line (U937), all expressing high levels of FcgRII on their cell surface, and T cells
(Jurkat), expressing close to no FcgRII (Fig. S2B). The presence of HBoV1 IgG antibodies
significantly enhanced the uptake of virus in all B cells and monocytes, evidenced by a
10- to 100-fold elevation of the viral loads (P , 0.001, Student’s t test) but had no
effect on the T cells (Fig. 5).
Furthermore, in Raji B cells, HBoV1-VLP-Alexa Fluor 488 fluorescence was signifi-
cantly enhanced during 8 h by the presence of HBoV1 IgG-containing serum (P , 0.01,
Student’s t test) (Fig. S3A). No significant difference in viral uptake was seen between
heated and nonheated serum, ruling against a role of complement in ADE (Fig. S3B).
Moreover, ADE was verified by a significant block of viral uptake in the two B-cell lines
and monocytes treated with mouse anti-human CD32 (FcgRII) or CD64 (FcgRI) antibod-
ies (P, 0.05, Student’s t test, Fig. 5). As opposed to these cells, HBoV1-specific antibod-
ies showed strong neutralization of the virus in permissive HAE cells (Fig. S4).
Endosomal localization of HBoV1 VLPs in B cells. To study how viral capsids enter
the cell, GM12878 B cells were exposed to fluorescent virus-like particles (VLPs) to-
gether with HBoV1-specific IgG. Confocal fluorescence imaging showed specific
FIG 5 Antibody-dependent enhancement (ADE) of HBoV1 infection in ex vivo-isolated tonsillar B cells, monocyte (U937), T-cell (Jurkat). and
two B-cell (Raji and GM12878-B) cultures, as well as blocking of Fc receptors of monocyte and two B-cell lines. Cells were infected at an MOI
of 100 genome copies per cell for 2 days in the presence of 10mg/ml total purified IgG with or without HBoV1 reactivity: HBoV1-positive (H1
IgG1) or -negative (H1 IgG2) IgG. For blocking of Fc receptors, cells were incubated with either anti-FcgRII (CD32) or anti-FcgRI (CD64)
antibodies or both before infection. Statistical significance by Student’s t test is indicated as follows: ns, not significant; *, P , 0.05, **, P ,
0.01, ***, P , 0.001. Please note the different scales of the y axes.
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intracellular localization of Alexa Fluor 488-labeled VLPs (Alexa Fluor 488-VLPs) in both
early and late endosomal (EEA1, Rab7) (Fig. 6A and B) as well as late endosomal/lysoso-
mal (LAMP-2) (Fig. 6C) marker-associated cytoplasmic vesicles.
Viral activity in ADE-infected B cells and monocytes. In follow-up cultures of
HBoV1 ADE-infected Raji B cells for up to 10 days, no net increase in DNA load was
seen by qPCR intracellularly (Fig. 7) or in the cell culture medium (data not shown),
suggesting that the infection was nonproductive.
Viral mRNAs were analyzed in ADE-infected ex vivo-cultured tonsillar B cells, as well
as U937 monocyte and Raji B-cell cultures. As a result, all three (NS1, VP, and spliced
NP1) mRNA transcripts were detected in the presence of HBoV1 IgG-positive but not of
HBoV1 IgG-negative sera (Fig. 8). In ADE-infected monocytes and Raji B cells, viral
mRNAs were undetectable after blocking of FcgRII (Fig. 8). The DNase I-treated RNA
preparations without reverse transcriptase (no-RT controls) were PCR negative, and the
FIG 6 Intracellular distribution of HBoV1 VLPs and endosomal markers. (A to C) Confocal imaging of HBoV1
VLPs-Alexa Fluor 488 (green) localization (arrow) within early endosomes (A), late endosomes (B), and
lysosomes (C). Representative optical sections of GM12878 cells incubated for 20 h with HBoV1 VLPs in the
presence of a positive serum pool. Close-up images show the regions where HBoV1 VLPs are localized within
early endosomes, late endosomes, or late endosomes/lysosomes, positive for EEA1, Rab7, or LAMP-2 markers,
respectively. Differential interference contrast (DIC) images merged with NucBlue staining (blue) are also
shown. Normalized fluorescence intensity line profiles of the intensity of VLPs (green) together with endosomal
and lysosomal markers (red) from the close-up regions are shown beside each image. Normalized fluorescence
intensity is shown in arbitrary units (a.u.). Bars, 2mm.
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PCR products amplified from the spliced NP1 transcripts were confirmed by sequenc-
ing to have the correct splicing site.
DISCUSSION
HBoV1 causes pediatric acute RTI, otitis media, and encephalitis and is able to per-
sist for months both in the airways, hampering PCR diagnosis, and in tonsil tissue (2–7,
11–17, 27–31). Tonsils could thus be reservoirs for virus excretion and spread. How and
where HBoV1 is able to infect and persist in the tonsils are not known. We investigated,
among nonviremic children with long-term HBoV1 immunity, where in tonsillar tissue
HBoV1 resides and whether the persisting virus is active or dormant. We detected viral
DNA in adenoid tonsils exclusively in the GCs, mostly in B cells and monocytes, and in
a proportion of T cells. Among the B cells, HBoV1 DNA persisted particularly in naive,
activated, and memory B-cell subpopulations, albeit in one high-viral-load adenoid,
also in plasmablasts. We further showed, in cultured tonsillar primary B cells, B-cell
lines and monocytes, but not in T cells, that HBoV1-specific IgG strongly enhanced vi-
FIG 7 Follow up of HBoV1 ADE infected Raji B cells. Cells were infected at a multiplicity of infection (MOI) of 100 and 1,000 viral genomes
per cell in the presence of various concentrations of purified total IgG with HBoV1 reactivity. Viral DNA copies were quantified at days 1, 3, 6,
and 10 postinfection. Triplicates are shown. Statistical significance by Student’s t test is indicated as follows: *, P , 0.05; **, P , 0.01; ***, P ,
0.001. Note that the y scale is logarithmic.
FIG 8 Viral mRNA expression in Raji B cells, U937 monocytes, and ex vivo-cultured tonsillar B cells.
The infection took place for 24 h in the presence of HBoV1 IgG-positive or -negative serum pools
(heat-inactivated serum; 1:100 diluted) or without serum. For FcgRII blocking, cells were preincubated
with anti-FcgRII (CD32) antibodies before infection, four replicates are shown. Viral NS1, NP1, and VP
mRNAs were quantified by reverse transcription-quantitative PCR (RT-qPCR), and viral mRNA copies
per million human reference mRNA, RPII, copies are presented. NB, FcgRII not blocked; B, FcgRII
blocked; pos pool, HBoV1 IgG-positive serum pool; neg pool, HBoV1 IgG-negative serum pool.
Xu et al. ®













































rus uptake leading to nuclear mRNA transcription and that this effect was inhibited by
blocking the cellular FcgRII.
Among other parvoviruses, the highly pathogenic Aleutian mink disease parvovirus
and human parvovirus B19 have, in the presence of antibodies, been shown to inter-
nalize via FcgR or the complement C1q receptor (CD93) into macrophages, endothelial
cells, or B cells, resulting in the establishment of persistent infection (23–26). Similarly,
the FcgR-mediated pathway of HBoV1 in our B-cell and monocyte cultures did not lead
to complete digestion of the virus for antigen presentation, instead the virus persisted
and at least some of them reached the nucleus, as evidenced by NS, NP, and VP mRNA
transcription. This endocytic pathway resembles the classical receptor-mediated endo-
cytosis, shown for another bocavirus (bovine parvovirus [BPV]), and could thus be
exploited by viruses (32–35). Indeed, in cultured B cells, we observed fluorescent HBoV1
VLPs to localize in early and late endosomes, in concordance with both the FcgRII-medi-
ated immune complex internalization route and the infection route of many parvoviruses;
e.g., canine parvovirus has been shown to exploit the cellular endocytic pathway to initiate
infection (34, 35).
The specific in vivo host cells, receptors, and uptake pathways for HBoV1 are unknown.
The virus is capable of productively infecting polarized pseudostratified epithelial cells,
mimicking the in vivo milieu of the airway epithelium and causing cell hypertrophy and
loss of cilia (2, 21, 22). HBoV1 DNA is very prevalent (up to 56%) in tonsillar tissues of chil-
dren with tonsillitis or hypertrophy without symptoms of RTI (11–18). A common treat-
ment for such ailments is removal of adenotonsillar tissue, which has been shown to
decrease the prevalence of particularly DNA viruses, like HBoV1 and adenoviruses, in the
nasopharynx (19–20). HBoV1 persistence in tonsils, by itself or in synergy with other
microbes, could perhaps trigger and/or maintain an inflammatory response in the tonsils
leading to chronic tonsillitis or hypertrophy.
Interestingly, HBoV1 DNA has been detected significantly more often in adenoid tonsils
than in palatine tonsils (12, 17). We likewise found HBoV1 DNA in only a single adult’s pala-
tine tonsil, as opposed to 54% of adenoid and 21% of palatine tonsils from children. In the
two patients with both types of tonsils available, the viral loads in adenoids were 24- and
5,900-fold higher. Furthermore, we were able to visualize by RISH, HBoV1 DNA in 4/7
adenoid as opposed to 1/7 palatine PCR-positive tonsils. Altogether, these data suggest
that adenoids could be a more favored persistence site for HBoV1 than palatine tonsils. In
contrast, parvovirus B19 has been shown to persist for life in the palatines (26). Perhaps
the infrequency of HBoV1 persistence among adults could reflect HBoV1’s apparent prefer-
ence for adenoids, which atrophy in adulthood. A reason for this predilection might be
that adenoids are covered by pseudostratified ciliated epithelium, whereas palatine tonsils
have stratified squamous epithelium. In our study, on the other hand, no viral nucleic acids
were seen by RISH beyond follicular GCs, ruling against epithelial persistent infection, even
if not against transient infection.
Even if HBoV1 has been shown to often persist in tonsils, the mRNA data revealing
viral activity, have been inconclusive (17, 18). In our study, HBoV1 DNA persisted in pe-
diatric adenotonsillar tissues at high prevalence; however, the diverse and often low vi-
ral loads (100 to 106 copies/106 cells) would rule against major productive replication.
This was corroborated by the infrequent mRNA transcription. Analogously, we saw no
net increase in viral DNA loads in B cells cultured for up to 10 days post-ADE, pointing
to nonproductive infection. Nevertheless, the RNase-resistant HBoV1 RISH signals of
our GCs revealed the presence of both the positive and negative DNA strands and of
both the left and right sides of the genome. Because human chromosomal DNA is
undetected by RISH, the observed viral DNA could not have been integrated. The posi-
tive-strand DNA must thus have originated from the 5% input virions or from dsDNA
after complementary strand synthesis or both. Its RISH signal was indeed weaker than
that of the negative-strand DNA, as expected of a predominantly negative-strand DNA
virus. The typical high particle-to-infectivity ratio in parvovirus infections makes it diffi-
cult to verify low-level replication in tissues. Nevertheless, having entered the nucleus
HBoV1 Infection in Tonsillar Germinal Centers ®













































at any cell cycle phase, HBoV1 is able to utilize the cellular DNA repair polymerase
primed by its own genome’s 39 hairpin terminus in order to synthesize the comple-
mentary strand (36). Indeed, by RT-PCR we detected unspliced NS1 mRNA (the no-RT
control being negative, ruling out interfering DNA amplification) in one adenoid tissue
and spliced HBoV1 mRNAs in cultures of ADE infected Raji B cells, monocytes, and ex
vivo tonsillar B cells. Since transcription initiation can occur only from dsDNA and the
cellular polymerases are located exclusively in the nucleus, the presence of viral mRNA
confirms that the ssDNA must have been converted into transcribable dsDNA and that
the virus has reached the nucleus (36). The mRNA-positive adenoid tissue had the
highest viral load by qPCR (2.9 106 copies/106 cells), permitting the detection of even
low-level NS1 transcripts. Parvoviral NS1 is a cytotoxic multifunctional protein with en-
donuclease, ATPase, and helicase activities, indispensable for virus replication, but
which can be expressed also in nonpermissive cells (2). It has furthermore been shown
to transactivate several host genes and to induce cell cycle arrest, DNA damage
response, and programmed cell death. Although it is not known whether NS1 is a pre-
requisite for HBoV1 persistence, the protein may be required for viral genome mainte-
nance in dividing cells. The 3-year-old child, with the mRNA-positive adenoid tissue,
was HBoV1 IgG positive (but HBoV2 and -3 IgG negative) yet lacked antiviral IgM and
viremia, ruling out acute HBoV1 infection. He underwent adenotonsillectomy due to
tonsillar hypertrophy and had an underlying genetic disorder, congenital insensitivity
to pain with anhidrosis (CIPA), which is not generally associated with abnormal virus
infections (37–39).
Contrary to B19V triggering apoptosis, acute HBoV1 infection of permissive HAE cul-
tures was recently shown to inhibit apoptosis but to promote the pyroptotic inflamma-
some-induced pathway involving caspase 1 (2, 40). Unlike apoptosis, pyroptosis results
in plasma membrane rupture, release of intracellular components, and virus spread.
The HBoV1 airway persistence could thus be due to tonsillar excretion of either encap-
sidated or naked viral DNA or to migratory virus-containing lymphocytes or macro-
phages. It has been suggested that viruses spread from the tonsils to the middle ear,
sinuses, or lungs, causing inflammation (27–31). In intestinal tissue, bocavirus DNA has
been shown to persist as episomes and to be excreted in feces, pointing to an analogy
with tonsils and airways (41, 42).
We showed that HBoV1 is retained in adenotonsillar GC B cells as dormant or
weakly transcribing viral genomes and that the virus in cultured tonsillar B cells is
taken up via ADE, likewise leading to mRNA transcription. To which extent this is a
common feature among tonsil-persistent viruses is not known. At least the HBoV1 B-
cell persistence, preferring pediatric adenoids, is dissimilar to that of parvovirus B19V,
preferring adult palatine tonsils (26). Moreover, adenovirus has been shown to persist
in tonsillar T cells, rather than B cells, with very low viral activity, yet it could be reacti-
vated upon in vitro lymphocyte stimulation, resulting in infectious virus production
(43, 44). Recently, silent influenza A virus, found in both B and T cells, could be rescued
from tonsillar persistency (45). Likewise, the quiescent HBoV1 genomes, even though
not as easily culturable, might be able to reactivate and replicate or translate proteins
with lytic, anti-apoptotic, pyroptotic, or inflammatory potential. A few studies describe
putative reactivations of HBoV1 persistence (7–10). Moreover, IgG-level fluctuations
have been observed during follow-up of children and adults, possibly implying reacti-
vation or reinfection of HBoV1 or infection by the related HBoV2 or HBoV3 (46, 47).
These enteric HBoVs are known to interfere with HBoV1 serology via cross-reactivity and
original antigenic sin (OAS), an immunological phenomenon first described for dengue
and influenza viruses, in which a prior infection interferes with the antibody production to
a subsequent infection by a related virus (47–50). It is tempting to speculate that HBoV1
persistence in GCs might regulate the FcgRII-mediated B-cell selection process leading to
OAS (51). Analogously, Epstein-Barr and measles viruses are known to infect B cells via
their respective receptors, CD21 and CD150, and to interfere with B-cell immune functions
(52, 53). It is possible that preexisting HBoV2 or HBoV3 immunity could mediate the
Xu et al. ®













































HBoV1 ADE infection of GCs, in line with the subsequent infections by dengue virus sero-
types (54–57). In our study, however, only 2 of the 12 HBoV1 DNA-positive children with
available serum had prior HBoV2 or HBoV3 immunity, suggesting that this would neither
be required nor frequent.
To conclude, we provide the first evidence of HBoV1 DNA persistence in pediatric
adenotonsillar GCs, predominantly in B cells and monocytes. Our data point to ADE-
mediated endocytic uptake of HBoV1 via FcgRII, leading to nuclear synthesis of comple-
mentary strand DNA and mRNA, yet with little or no productive replication. Whether
the persistent virus can alter GC functions, be released by cellular pyroptosis account-
ing for the long-lived PCR positivity in nasopharyngeal mucosa, or be reactivated by
other viruses or immunosuppression, must be determined in forthcoming studies.
MATERIALS ANDMETHODS
Patients and tissue preparation. Tonsillar samples were collected in spring 2015 and in winter
2019 at the Helsinki University Hospital from a total of 41 patients #10 years of age (median, 5.96 years)
and from 38 patients 10 to 69 years of age (median, 26.5 years), who underwent tonsillar surgery (tonsil-
lectomy, tonsillotomy, or adenoidectomy) for chronic tonsillitis or tonsillar hypertrophy. In 2019, of 14
children, four provided tissue of only adenoids, one of both left and right tonsils, and nine of both
adenoids and tonsils. In 2015, 27 children #10 years of age and all the 38 patients aged .10 years, pro-
vided right-side tonsils only. The patients lacked acute respiratory symptoms during the 2 weeks before
surgery. Informed consent was obtained from all patients or children’s parents. The study protocol was
approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa, and institutional
research permission was granted by the Department of Otorhinolaryngology, Helsinki University
Hospital, Helsinki, Finland.
Tissues collected during 2019 were processed immediately as three distinct preparations (Preps 1, 2
and 3). Two pieces of tonsil, for respective DNA and RNA purification, were immersed immediately after
surgery in RNAlater overnight, and then stored at 220°C (Prep 1), while two other pieces were freshly
frozen, then embedded in OCT compound, and stored at 280°C (Prep 2). The remaining tissue was
placed in cold phosphate-buffered saline (PBS) and stored at 14°C until mechanical homogenization
with a syringe plunger. The homogenate was then treated with collagenase, 0.1mg/ml Liberase TL
(Roche), at 37°C for 30min, and the cell preparations were filtered through a 70-mm nylon mesh, washed
twice with PBS, and stored in liquid nitrogen (Prep 3). The tonsillar tissues collected in 2015 were ho-
mogenized as Prep 3 above but were not treated with collagenase (26). Serum samples were obtained
from all the pediatric patients, except two enrolled in 2015, and studied for HBoV1 DNA and HBoV1-3-
specific antibodies.
Details of DNA and mRNA extraction and PCR amplification from tonsillar tissues and cell cultures, as
well as HBoV1 virus production are described in Text S1 in the supplemental material. Primers and
probes are listed in Table 1.
Magnetic positive selection of cell fractions. To investigate the cell types of HBoV1 persistence,
three populations were isolated sequentially from HBoV1 DNA-positive tonsils (Prep 3) using CD anti-
body-coupled magnetic beads (Dynabeads; Invitrogen), according to the manufacturer’s instructions: T
cells with anti-CD3 beads, B cells with anti-CD19 beads for the CD3-depleted cells, and monocytes with
anti-CD14 beads for the CD3-CD19-depleted cells. To test the purity of the three isolates, cells from the
beads were released with DETACHaBEADS (Invitrogen), and labeled with anti-human CD19-FITC (CD19
labeled with fluorescein isothiocyanate) (clone SJ25-C1; Invitrogen), CD3-PE/Cy5.5 (CD3 labeled with
phycoerythrin or Cy5.5) (clone UCHT1; Abcam), or CD14-PE (clone MwP9; BD Biosciences) and analyzed
on a BD Accuri C6 flow cytometer as described previously (26). Assessment of the cell fraction propor-
tions is described in Text S1.
B-cell sorting. To characterize the B-cell subpopulation(s) harboring HBoV1 DNA, tonsillar cell Prep
3 was sorted with multicolor fluorescence-activated cell sorting (FACS) on a BD Influx Cell Sorter based
on cell viability (7-aminoactinomycin D [7AAD]; Invitrogen) and according to the cellular markers (anti-
human CD19-PE [clone CB19; Abcam], CD20-PE-Cy7 [clone 2H7; Biolegend], IgD-allophycocyanin [APC]-
Cy7 [clone IA6-2; Biolegend], CD27-FITC [clone LT27; Abcam], and CD38-BV421 [clone HB-7; Biolegend]).
Four subsets of B cells (CD191) were sorted: naive (CD201 IgD1 CD272), memory (CD201 IgD2 CD271),
and activated B cells (CD201 IgD1 CD271) and plasmablasts (CD202 IgD2 CD271 CD381), and one ali-
quot of each cell subset was stored at 220°C for viral DNA detection. The remaining cells were fixed
with 4% paraformaldehyde at 37°C, resuspended in 70% ethanol, and cytocentrifuged (800 rpm, 20min)
onto glass slides (SuperFrost Plus), followed by HBoV1 RNAscope in situ hybridization (RISH) staining as
described below.
Human serum, purified IgG, and IgG EIA. Human sera were pooled from 6 individuals with, and
from 11 individuals without, HBoV1 IgG reactivity, in two pools. The individual and pooled sera as well
as all pediatric sera were tested for HBoV1, -2, and -3 IgG by competitive, and IgM by non-competitive,
enzyme immunoassays (EIAs) as previously described (58, 59). The serum pools were examined with or
without heat inactivation for 30min at 56°C. Total IgG was purified from the pools by HiTrap protein A
HP (GE Healthcare) columns. Protein concentrations were measured with Pierce BCA (Thermo Fisher
Scientific).
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Antibody-dependent enhancement. To determine antibody-dependent enhancement (ADE),
GM04671 (Raji) and GM12878 lymphoblastoid B-cell lines (both from Coriell Institute) and U937 mono-
cyte line (ATCC CRL-1593.2) and ex vivo tonsillar B cells were cultured in RPMI, supplemented with 10%
fetal bovine serum, and infected with HBoV1 (see Text S1 for virus production) in the presence of puri-
fied total IgG or serum, with or without HBoV1 reactivity. Briefly, 2 105 cells were cultured on a 96-well
plate and infected with HBoV1 particles at a multiplicity of infection (MOI) of 100 viral genome copies
per cell for 48 h in the presence of 10mg/ml of purified total HBoV1-positive or -negative IgG. Infected
and uninfected cells without IgG or serum served as controls. After culture, cells were treated with
0.25% trypsin-EDTA (Gibco) for 15min at 37°C to remove surface-bound virus, washed three times with
cold PBS, and suspended in 200ml PBS for viral DNA and mRNA quantification. ADE with Alexa Fluor-la-
beled VLPs and neutralization of HBoV1 in HAE cells are described in Text S1.
Blocking of cellular Fc receptors. To confirm that HBoV1 IgG enhanced viral uptake through the Fc
receptors in two B-cell lines and the monocyte line, a total of 2 105 cells were incubated with purified
mouse anti-CD32 (clone 3D3; BD Biosciences) for FcgRII, anti-CD64 (clone 10.1; BD Biosciences) for FcgRI,
or both, at 10mg/ml for 1h at 37°C, followed by the ADE assay and qPCR, as described above. The cells
were cultured for 40 h, trypsinized, and washed as described above. The presence of Fc receptors on pri-
mary B cells and cell lines was assessed by flow cytometry (Text S1).
Confocal imaging. For microscopy, GM12878 B cells were incubated with fluorescent HBoV1 VLP-
Alexa Fluor 488 for 20 h in the presence of the HBoV1 IgG-positive serum pool (1:100 diluted) and then
treated with 500mM NH4Cl for 4min at room temperature to remove noninternalized surface-bound
VLPs. Cells were air dried overnight on high-performance cover glasses (0.17-mm thickness, 18 18
mm2; Carl Zeiss), fixed with 4% paraformaldehyde for 15min at room temperature, and permeabilized
with 0.1% Triton X-100 in PBS supplemented with 0.5% bovine serum albumin (BSA) and 0.01% sodium
azide for 15min. Early endosomes, late endosomes, and late endosomes/lysosomes were visualized with
primary mouse or rabbit antibodies against EEA1 (ab2900; Abcam), Rab7 (ab137029;Abcam) and LAMP-2
(9840-01 mouse anti-human CD07b-UNLB; DSHB Developmental Studies Hybridoma Bank), respectively.
The primary antibodies were followed by secondary Alexa Fluor 555-conjugated goat anti-mouse and
goat anti-rabbit antibodies (Thermo Fisher Scientific) and mounted in ProLong Glass Antifade Mountant
with NucBlue (Invitrogen) and imaged as described in Text S1.
RNAscope in situ hybridization and immunohistochemistry. To identify the adenotonsillar persist-
ence site, RNAscope ISH (RISH) technology (Advanced Cell Diagnostics [ACD], Newark, CA) was used for
viral RNA or DNA detection. Fresh-frozen tonsils in OCT were cut into 20-mm-thick sections in a cryostat
at 220°C, dried on glass slides (SuperFrost Plus) at 220°C for 1 h, and fixed with 4% paraformaldehyde
for 1 h on ice. HBoV1 nucleic acid was detected using paired double-Z oligonucleotide probes against
target HBoV1-VP3 positive-sense DNA or mRNA (RNAscope Probe-V-HBoV1-VP, 28 to 1,001 bp; 20 pairs;
GenBank accession no. KF385975.1) and HBoV1-NS negative-sense DNA (RNAscope Probe-V-HBoV1-NS-
TABLE 1 Primers and probes used for qPCRs in the study
Gene Primer and probea
GenBank
accession no.
NP1mRNA 59-CGGCGAGTGAACATCTCTGGA-39 (203–223) NC_007455
59-TGCTTGTCTTTCATATTCCCT-39 (2438–2418)
59-FAM-TGTCCACCCAAGAAACGTCGTCTAA-BHQ1-39
NS1mRNAb 59-GTTGGTCACGCCCTGTGCT-39 (1549–1567) JQ923422
59-AATCCCTTGGACGATTGCCT-39 (1649–1668)
59-FAM-TTTGCTTTTACGGGCCTGCCTCA-BHQ1-39
VPmRNAb and DNA 59-TAGACGCACCACAGAACACC-39 (3579–3598) JQ923422
59-AAGTGAGAACCTCCGACCCA-39 (3665–3684)
59-FAM-AGGAAGTATTGGAGGAGGAAAAGGAT-BHQ1-39
RPIImRNA 59-GCACCACGTCCAATGACAT-39 (838–856) X74870
59-GTGCGGCTGCTTCCATAA-39 (1452–1469)
59-FAM-TACCACGTCATCTCCTTTGATGGCTCCTA-BHQ1-39
NS1 DNA 59-CCTATATAAGCTGCTGCACTTCCTG-39 (152–177) NC_007455
59-AAGCCATAGTAGACTCACCACAAG-39 (235–259)
59-FAM-CCAGAG ATGTTCACTCGCCG-BHQ1-39
RNase P 59-GAGGGAAGCTCATCAGTGGGG-39 (9–29) NR_002312.1
DNA 59-CCCTAGTCTCAGACCTTCCCAAG-39 (70–92)
59-FAM-AGTGCGTCCTGTCACTCCACTC-TAMRA-39
aFAM, 6-carboxyfluorescein; BHQ, black hole quencher; TAMRA, 6-carboxytetramethylrhodamin.
bNote that as NS1 and VP RT-PCRs are not specific for the major protein-coding mRNAs, alternatively spliced
transcripts for the other proteins may also be detected by these primers and probes. For a transcription map of
the HBoV1 genome, please see reference 2. NP1, nuclear phosphoprotein 1; NS1, nonstructural protein 1; VP,
virus capsid protein; RPII, cellular RNA polymerase II; RNase P, cellular RNase P.
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sense, 1,152 to 2,267 bp, 20 pairs; GenBank accession no. JQ923422.1). RNAscope 2.5 HD reagent kit-RED
(PN 322350; ACD) was employed according to the manufacturer’s protocol, presenting the targets as red
dots. Hybridization was done in an ACD HybEZ II oven. Probes targeting the human housekeeping gene
PPIB and the bacterial gene dapB (ACD) served as positive and negative controls, respectively. To differ-
entiate between viral DNA and mRNA signals, RNase A (5mg/ml, 40°C for 30min; Qiagen) was applied to
the sections before RISH.
For cell typing, a B-cell marker (mouse anti-human CD20 monoclonal antibody [mAb], clone L26,
Biocare Medical) was employed after RISH, by chromogenic immunohistochemistry (IHC) using the
MACH1 Universal HRP-Polymer detection kit (Biocare Medical). Sections were counterstained with hema-
toxylin and mounted with VectaMount medium (Vectorlabs).
Bright-field images were generated with a 40 objective with extended focus using 3DHISTECH
Pannoramic 250 FLASH II digital slide scanner at the Genome Biology Unit, supported by HiLIFE and the
Faculty of Medicine, University of Helsinki, Finland.
Statistical analysis. Student’s t test was used for analysis of statistical significance of viral loads in
two independent groups. These analyses were conducted using GraphPad Prism 7 software (San Diego,
CA). Differences were considered statistically significant at P, 0.05.
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